Page 8 - CiTRUS Demo

Our core: evidence strategy and planning
EARLY STAGE LATE STAGE LAUNCH PREP
Evolving, Understanding and Market Refining
Informing Late-Stage Development
Market Understanding
• Problems and Unmet Needs – clinical and cost burden, prognosis, disease progression,
safety, etc.
• Current treatment – drug use, surgery, treatment algorithms
• Market sizing – incidence, prevalence, duration of treatment
• Understanding patient populations – treatments received by patient type,
outcomes by patient type or treatment
• Natural history of disease
Informing Development
• Trial design – use real-world data to inform trial design
(i.e. patient inclusion/exclusion criteria, feasibility assessment and clinical points)
• Regulatory – resource use, reimbursement – gain real
world understanding of burden of illness, such as: HRQoL, cost-effectiveness, utility
Clarity of What is Valuable
Demonstrating Value
• Informing post-launch – what do physicians, payers and patients consider value (efficacy, HRQoL, costs) Competitor analysis – likely effectiveness targets required to displace established competitors, potential safety benefits, potential cost-savings
• HEOR – Cost-effective modelling, budget impact models
8